← Back to Search

Monoclonal Antibodies

Gevokizumab for Colon Cancer

Phase 2
Waitlist Available
Led By Norman Wolmark, MD
Research Sponsored by NSABP Foundation Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the initiation of study therapy through 1 year of follow-up
Awards & highlights

Study Summary

This trial will test if gevokizumab can improve survival in patients with MSS colon cancer that has come back after treatment and who have ctDNA.

Eligible Conditions
  • Colon Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the initiation of study therapy through 1 year of follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the initiation of study therapy through 1 year of follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrence-free survival (RFS) at one year
Secondary outcome measures
Clearance of ctDNA
Duration of Recurrence-free survival (RFS) with ctDNA clearance at 8 weeks from start of study therapy
Duration of Recurrence-free survival (RFS) without ctDNA clearance at 8 weeks
+3 more

Side effects data

From 2016 Phase 1 & 2 trial • 8 Patients • NCT01835132
25%
Upper respiratory tract infection
25%
Urinary tract infection
13%
Asthenia
13%
Rhinorrhoea
13%
Ocular hyperaemia
13%
Headache
13%
Renal failure
13%
Hepatic enzyme increased
13%
Hyperlipidaemia
13%
Road traffic accident
13%
Dizziness
13%
Muscle strain
13%
Hemoglobin urine present
13%
Decreased appetite
13%
Infection
13%
Oropharyngeal pain
13%
Corneal thinning
13%
Haemorrhoids
13%
Nausea
13%
Fatigue
13%
Biopsy skin
13%
Hordeolum
13%
Nasopharyngitis
13%
Sinusitis
13%
Scleral thinning
13%
Dry skin
13%
Foreign body in eye
13%
Bacterial test
13%
Haematuria
13%
Influenza
13%
Influenza like illness
13%
Irritable bowel syndrome
13%
Joint injury
13%
Laceration
13%
Limb injury
13%
Lymph node pain
13%
Pruritis generalized
13%
Rash
13%
Tooth fracture
13%
Erythema
13%
Injection site discomfort
13%
Abdominal pain
13%
Hypotension
100%
80%
60%
40%
20%
0%
Study treatment Arm
Gevokizumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: Arm 1Experimental Treatment2 Interventions
ctDNA positive Gevokizumab for 1 year (maximum of 13 cycles)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gevokizumab
2013
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

NSABP Foundation IncLead Sponsor
86 Previous Clinical Trials
136,988 Total Patients Enrolled
Novartis PharmaceuticalsIndustry Sponsor
2,855 Previous Clinical Trials
4,197,350 Total Patients Enrolled
Natera, Inc.Industry Sponsor
47 Previous Clinical Trials
42,367 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
2022. "A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05178576.
~0 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top